Skip to content
MARKETS / NASDAQ / ICCC
NASDAQ · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · SMALL CAP

Immucell Corp. ICCC

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$27.6M
▲ 4.3% YoY
$-1.0M
$1.2M
In brief

What this company does

ImmuCell Corporation, founded in 1982 and a SEC-registered public company since 1987, is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. The Company’s primary product line, First Defense®, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. We currently have 73 employees who are engaged primarily in quality and manufacturing operations, sales and marketing, product development and finance and administration. As a public reporting company, we file quarterly and annual reports with the Securities and Exchange Commission (SEC) on Form 10-Q and Form 10-K, respectively.

Written from the business description in ImmuCell Corporation's annual report to the U.S. Securities and Exchange Commission, filed 30 March 2026. Every sentence was checked against that document before publication.

Growth
USD 27.6M
Revenue, FY2025 · full 17-year series below
Revenue $M Net income $M
FY2025 · Revenue 27.6 · Net income -1.0
10M20M-2M-4M200920112013201520172019202120232025
Compound annual growth
+14.2%
+12.5%
+10.5%
+13.1%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +12.5% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−4 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating 6.0% · Net -3.8%
10%20%-10%-20%-30%200920112013201520172019202120232025
ROE
FY2025 · ROE -3.8%
5%10%-10%-20%200920112013201520172019202120232025

Each USD of equity lost 4 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 1.2
-8M-16M200920112013201520172019202120232025

Total assetsUSD 42.5M
EquityUSD 27.1M
CashUSD 3.8M
Gross debtUSD 9.1M
Net debtUSD 5.3M
Current ratio4.26×

Net debt stands at 20% of equity.

The 17-year record
17 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.00.00.0−0.0−0.00.0−0.0−0.0−0.0
EBITDA $B0.00.0−0.00.00.00.00.00.00.00.00.00.00.00.0−0.0−0.0−0.0
Income tax $B0.00.00.00.00.0−0.00.00.0−0.00.00.0−0.00.00.0−0.0−0.0−0.0
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.00.0−0.00.00.0−0.0−0.0−0.0
Free cash flow $B0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.0−0.00.00.0−0.0−0.0−0.0
EPS, diluted $−0.12−0.26−0.75−0.32−0.01−0.14−0.19−0.42−0.030.120.38−0.060.040.03−0.14−0.13−0.07
Dividend / sh $·················
Payout %·················
ROE %−3.8−8.2−20.9−7.9−0.3−3.6−5.1−10.2−0.83.412.2−1.81.31.0−4.5−4.1−2.2
Shares out B0.010.010.010.010.010.010.010.010.010.000.00······

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 83 reconciliationsAUDITED

Reconciled in 17 of 19 fiscal years. 12 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityIn Vitro & In Vivo Diagnostic Substances
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2009

Share this section

Download image